Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic name - Glatiramer acetate) is medication FDA approved for the treatment of multiple sclerosis. Copaxone\'s high safety profile has been documented in large cohorts of patients for more than 12 years.
Epistemonikos ID: f725ccfd7a9a0cb3bb8ed05b64e1d09fa21e1022
First added on: May 11, 2024